To Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis

Launched by KOREA ARLICO PHARM. CO., LTD · Jul 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new medicine called ALC-2203 to see if it is safe and helps people with acute bronchitis, which is a sudden inflammation of the airways that causes coughing and mucus. The study is currently looking for adults aged 19 and older who have recently developed symptoms of acute bronchitis within the last 48 hours, and who have a certain level of cough and mucus based on a simple score used by doctors.

If you join the trial, you may receive either the new medicine, a placebo (a treatment with no active medicine), or another medicine for comparison. The study is “double-blind,” meaning neither you nor the doctors will know which treatment you are getting, to make the results more reliable. People with serious lung diseases like asthma or chronic bronchitis, or those already taking cough medicines like codeine or dextromethorphan, cannot join. Participants will be asked to visit the clinic for check-ups and share information about their symptoms during the study. This trial is important because it may help find better treatments for acute bronchitis in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male and female participants aged 19 years or older.
• 2. Patients diagnosed with acute bronchitis with:
• • A Bronchitis Severity Score (BSS) of ≥ 5 at Visit 2.
• • A sputum subscore of at least 1 at Visit 2.
• • 3. Onset of acute bronchitis symptoms within 48 hours prior to Visit 2.
• • 4. Patients who voluntarily agree to participate
• Exclusion Criteria:
• • 1. Patients who, in the opinion of the investigator, have severe respiratory diseases such as allergic asthma, chronic bronchitis, or asthma
• • 2. Patients who are currently taking, or are expected to take during the study period, antitussive or expectorant medications containing agents such as codeine or dextromethorphan
• • 3. Patients who have participated in another clinical trial within 4 weeks prior to screening